Bioventus files 8-K, furnishes Q3 results press release

Rhea-AI Filing Summary

Bioventus Inc. (BVS) reported results for the three and nine months ended September 27, 2025. The company announced these financial results via a press release furnished as Exhibit 99.1 to a Form 8-K.

The information in Item 2.02, including Exhibit 99.1, is furnished, not filed, and is not subject to Section 18 liabilities, nor incorporated by reference unless expressly stated. The filing also lists Exhibit 104, the cover page Inline XBRL data.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001665988FALSE00016659882025-11-042025-11-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2025

Bioventus Inc.

(Exact name of registrant as specified in charter)

Delaware

001-37844

81-0980861

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification Number)

4721 Emperor Boulevard, Suite 100

Durham, North Carolina 27703

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (919) 474-6700

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17     CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A common Stock, $0.001 par value per share

BVS

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☒

Item 2.02.    Results of Operations and Financial Condition.

On November 4, 2025, Bioventus Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 27, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

Item 9.01.    Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.						Description
99.1						Press Release Dated November 4, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			BIOVENTUS INC.
Date: November 4, 2025			By:			/s/ Anthony D’Adamio
						Anthony D’Adamio Senior Vice President and General Counsel

FAQ

What did Bioventus (BVS) announce in this 8-K?

Bioventus reported financial results for the three and nine months ended September 27, 2025, via a press release furnished as Exhibit 99.1.

Is the Bioventus Q3 2025 results press release filed or furnished?

It is furnished, not filed, and is not subject to Section 18 liabilities or incorporated by reference unless expressly stated.

Which exhibits are included with Bioventus’s 8-K?

The filing includes Exhibit 99.1 (press release) and Exhibit 104 (cover page Inline XBRL data).

What period do the Bioventus results cover?

They cover the three and nine months ended September 27, 2025.

What exchange and ticker does Bioventus trade under?

Bioventus Class A common stock trades on the Nasdaq Global Select Market under the symbol BVS.